Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 307-311

  Chan, John K ^a   Tian, Chunqiao ^b   Teoh, Deanna ^a   Monk, Bradley J ^c   Herzog, Thomas ^d   Kapp, Daniel S ^e   Bell, Jeffrey ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Early stage; Ovarian cancer; Recurrent; Survival

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DEMOGRAPHY; DISEASE FREE INTERVAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; EARLY CANCER; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 75749104593     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.074     Document Type: Article

References (20)

1. American Cancer Society. Cancer facts and figures 2007. Available at: .
2. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. Int. J. Gynaecol. Obstet. 83 Suppl 1 (2003) 135-166
3. Ozols R.F., Dembo A.J., and Robboy S. Epithelial ovarian cancer. In: Hoskins W.J.P.C., and Young R.C. (Eds). Principles and Practice of Gynecologic Oncology (1992), Lippincott, Philadelphia 731-781
4. Chan J.K., Tian C., Monk B.J., et al. Prognostic factors for high-risk early-stage 439 epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 112 440 (2008) 2202-2210
5. Kolomainen D.F., A'Hern R., Coxon F.Y., et al. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?. J. Clin. Oncol. 21 (2003) 3113-3118
6. Bell J., Brady M.F., Young R.C., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 102 (2006) 432-439
7. D. Collett, Modelling Survival Data In Medical Research (2nd Ed). Chapman and Hall/CRC 2003.
8. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
9. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351 (2004) 2489-2497
10. Dembo A.J., Davy M., Stenwig A.E., et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. 75 (1990) 263-273
11. Sevelda P., Vavra N., Schemper M., et al. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 65 (1990) 2349-2352
12. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322 (1990) 1021-1027
13. Finn C.B., Luesley D.M., Buxton E.J., et al. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br. J. Obstet. Gynaecol. 99 (1992) 54-58
14. Vergote I.B., Kaern J., Abeler V.M., et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am. J. Obstet. Gynecol. 169 (1993) 40-52
15. Bertelsen K., Holund B., Andersen J.E., et al. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int. J. Gynecol. Cancer 3 (1993) 211-218
16. Sjovall K., Nilsson B., and Einhorn N. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int. J. Gynecol. Cancer 4 (1994) 333-336
17. Ahmed F.Y., Wiltshaw E., A'Hern R.P., et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J. Clin. Oncol. 14 (1996) 2968-2975
18. Trope C., Kaern J., Hogberg T., et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann. Oncol. 11 (2000) 281-288
19. Markman M., Rothman R., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9 (1991) 389-393
20. Gore M.E., Fryatt I., Wiltshaw E., et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36 (1990) 207-211